Tr-PEG5-OH |
| Catalog No.GC67168 |
Tr-PEG5-OH est un lieur PEG ADC à 5 unités non clivable utilisé dans la synthèse de conjugués anticorps-médicament (ADC). Tr-PEG5-OH est un lieur PROTAC à base de PEG qui peut être utilisé dans la synthèse des PROTAC.
Products are for research use only. Not for human use. We do not sell to patients.
Cas No.: 141282-24-8
Sample solution is provided at 25 µL, 10mM.
;)
,-1-7$$$37316672.jpg');)
;)
;)
$$$36806353.jpg');)
;33(7)%EF%BC%9A546-561$$$37156877.jpg');)
;)
;)
;)
%201124-1138.$$$35908550.jpg');)
%20766-780.$$$37100057.jpg');)
%20418-432.$$$36893736.jpg');)
%EF%BC%9A-240-255.$$$35108512.jpg');)
533-545$$$36543525.jpg');)
%201-13.$$$36600053.jpg');)
;)
Tr-PEG5-OH is a non-cleavable 5 unit PEG ADC linker used in the synthesis of antibody-drug conjugates (ADCs). Tr-PEG5-OH is a PEG-based PROTAC linker can be used in the synthesis of PROTACs.
ADCs are comprised of an antibody to which is attached an ADC cytotoxin through an ADC linker[1].
PROTACs contain two different ligands connected by a linker; one is a ligand for an E3 ubiquitin ligase and the other is for the target protein. PROTACs exploit the intracellular ubiquitin-proteasome system to selectively degrade target proteins[1].
[1]. Branderhorst HM, et al. Strong inhibition of cholera toxin binding by galactose dendrimers. Chem Commun (Camb). 2007 Dec 21;(47):5043-5.
[2]. An S, et al. Small-molecule PROTACs: An emerging and promising approach for the development of targeted therapy drugs. EBioMedicine. 2018 Oct;36:553-562.
Average Rating: 5 (Based on Reviews and 30 reference(s) in Google Scholar.)
GLPBIO products are for RESEARCH USE ONLY. Please make sure your review or question is research based.
Required fields are marked with *